This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Alector stock | $12.73

Own Alector stock in just a few minutes.

Posted

Fact checked

Alector, Inc is a biotechnology business based in the US. Alector shares (ALEC) are listed on the NASDAQ and all prices are listed in US Dollars. Alector employs 153 staff and has a trailing 12-month revenue of around USD$19 million.

How to buy shares in Alector

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Alector. Find the stock by name or ticker symbol: ALEC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alector reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$12.73, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Alector, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Alector. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Alector share price

Use our graph to track the performance of ALEC stocks over time.

Alector shares at a glance

Information last updated 2020-10-20.
Latest market close USD$12.73
52-week range USD$9.35 - USD$35.93
50-day moving average USD$11.6566
200-day moving average USD$20.7446
Wall St. target price USD$34.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.255

Buy Alector shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Alector stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alector price performance over time

Historical closes compared with the close of $12.73 from 2020-11-16

1 week (2020-11-25) -4.21%
1 month (2020-11-06) 11.96%
3 months (2020-09-04) 2.58%
6 months (2020-06-05) -57.55%
1 year (2019-12-05) -34.35%
2 years (2018-12-02) N/A
3 years (2017-12-02) N/A
5 years (2015-12-02) N/A

Alector financials

Revenue TTM USD$19 million
Gross profit TTM USD$-79,309,000
Return on assets TTM -18.48%
Return on equity TTM -49.12%
Profit margin 0%
Book value $4.484
Market capitalisation USD$745.5 million

TTM: trailing 12 months

Shorting Alector shares

There are currently 10.7 million Alector shares held short by investors – that's known as Alector's "short interest". This figure is 26.6% up from 8.4 million last month.

There are a few different ways that this level of interest in shorting Alector shares can be evaluated.

Alector's "short interest ratio" (SIR)

Alector's "short interest ratio" (SIR) is the quantity of Alector shares currently shorted divided by the average quantity of Alector shares traded daily (recently around 938539.13808267). Alector's SIR currently stands at 11.37. In other words for every 100,000 Alector shares traded daily on the market, roughly 11370 shares are currently held short.

However Alector's short interest can also be evaluated against the total number of Alector shares, or, against the total number of tradable Alector shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alector's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Alector shares in existence, roughly 130 shares are currently held short) or 0.2341% of the tradable shares (for every 100,000 tradable Alector shares, roughly 234 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Alector.

Find out more about how you can short Alector stock.

Alector share dividends

We're not expecting Alector to pay a dividend over the next 12 months.

Alector overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site